These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 30036569)

  • 41. Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease.
    von Euler Chelpin M; Söderberg L; Fälting J; Möller C; Giorgetti M; Constantinescu R; Blennow K; Zetterberg H; Höglund K
    J Parkinsons Dis; 2020; 10(4):1429-1442. PubMed ID: 33016895
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson's Disease and Atypical Parkinsonian Syndromes.
    Kaiserova M; Chudackova M; Prikrylova Vranova H; Mensikova K; Kastelikova A; Stejskal D; Kanovsky P
    Neurodegener Dis; 2021; 21(1-2):30-35. PubMed ID: 34695830
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls.
    Herbert MK; Eeftens JM; Aerts MB; Esselink RA; Bloem BR; Kuiperij HB; Verbeek MM
    Parkinsonism Relat Disord; 2014 Jan; 20(1):112-5. PubMed ID: 24075122
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders.
    Schulz I; Kruse N; Gera RG; Kremer T; Cedarbaum J; Barbour R; Zago W; Schade S; Otte B; Bartl M; Hutten SJ; Trenkwalder C; Mollenhauer B
    Mov Disord; 2021 Dec; 36(12):2874-2887. PubMed ID: 34363416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls.
    Marques TM; van Rumund A; Bruinsma IB; Wessels HJCT; Gloerich J; Esselink RAJ; Bloem BR; Kuiperij HB; Verbeek MM
    Mol Neurobiol; 2019 Jul; 56(7):5067-5074. PubMed ID: 30465235
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy.
    Compta Y; Giraldo DM; Muñoz E; Antonelli F; Fernández M; Bravo P; Soto M; Cámara A; Torres F; Martí MJ;
    Parkinsonism Relat Disord; 2018 Jan; 46():16-23. PubMed ID: 29107645
    [TBL] [Abstract][Full Text] [Related]  

  • 47. α-Synuclein seed amplification assay as a diagnostic tool for parkinsonian disorders.
    Fernandes Gomes B; Farris CM; Ma Y; Concha-Marambio L; Lebovitz R; Nellgård B; Dalla K; Constantinescu J; Constantinescu R; Gobom J; Andreasson U; Zetterberg H; Blennow K
    Parkinsonism Relat Disord; 2023 Dec; 117():105807. PubMed ID: 37591709
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis.
    Eusebi P; Giannandrea D; Biscetti L; Abraha I; Chiasserini D; Orso M; Calabresi P; Parnetti L
    BMJ Open; 2016 Jun; 6(6):e011113. PubMed ID: 27297011
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson's Disease and Atypical Parkinsonian Syndromes.
    Fujita H; Suzuki K; Numao A; Watanabe Y; Uchiyama T; Miyamoto T; Miyamoto M; Hirata K
    PLoS One; 2016; 11(11):e0165869. PubMed ID: 27812167
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.
    Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L
    Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Differential diagnosis of parkinsonian syndromes using MRI].
    Mahlknecht P; Schocke M; Seppi K
    Nervenarzt; 2010 Oct; 81(10):1168-79. PubMed ID: 20857276
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.
    Bäckström DC; Eriksson Domellöf M; Linder J; Olsson B; Öhrfelt A; Trupp M; Zetterberg H; Blennow K; Forsgren L
    JAMA Neurol; 2015 Oct; 72(10):1175-82. PubMed ID: 26258692
    [TBL] [Abstract][Full Text] [Related]  

  • 54. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders.
    Herbert MK; Aerts MB; Beenes M; Norgren N; Esselink RA; Bloem BR; Kuiperij HB; Verbeek MM
    Front Neurol; 2015; 6():91. PubMed ID: 25999911
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantitative susceptibility mapping and blood neurofilament light chain differentiate between parkinsonian disorders.
    Zhang P; Chen J; Cai T; He C; Li Y; Li X; Chen Z; Wang L; Zhang Y
    Front Aging Neurosci; 2022; 14():909552. PubMed ID: 35992605
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The contribution of cerebellar proton magnetic resonance spectroscopy in the differential diagnosis among parkinsonian syndromes.
    Zanigni S; Testa C; Calandra-Buonaura G; Sambati L; Guarino M; Gabellini A; Evangelisti S; Cortelli P; Lodi R; Tonon C
    Parkinsonism Relat Disord; 2015 Aug; 21(8):929-37. PubMed ID: 26077167
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes.
    Starhof C; Hejl AM; Heegaard NHH; Carlsen AL; Burton M; Lilje B; Winge K
    Mov Disord; 2019 Feb; 34(2):246-254. PubMed ID: 30557454
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Card-type Odor Identification Test for Japanese Patients with Parkinson's Disease and Related Disorders.
    Watanabe Y; Suzuki K; Miyamoto T; Miyamoto M; Numao A; Fujita H; Uchiyama T; Kadowaki T; Matsubara T; Hirata K
    Intern Med; 2017 Nov; 56(21):2871-2878. PubMed ID: 28943542
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CSF α-Synuclein Seed Amplification Assay in Patients With Atypical Parkinsonian Disorders.
    Anastassiadis C; Martinez-Valbuena I; Vasilevskaya A; Thapa S; Hadian M; Morales-Rivero A; Mora-Fisher D; Salvo C; Taghdiri F; Sato C; Moreno D; Anor CJ; Misquitta K; Couto B; Tang-Wai DF; Lang AE; Fox SH; Rogaeva E; Kovacs GG; Tartaglia MC
    Neurology; 2024 Sep; 103(6):e209818. PubMed ID: 39208367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.